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Abstract
Background: Affinity chromatography is one of the most efficient protein purification strategies. This technique
comprises a one-step procedure with a purification level in the order of several thousand-fold, adaptable for
various proteins, differentiated in their size, shape, charge, and other properties. The aim of this work was to verify
the possibility of applying affinity chromatography in bacteriophage purification, with the perspective of
therapeutic purposes. T4 is a large, icosahedral phage that may serve as an efficient display platform for foreign
peptides or proteins. Here we propose a new method of T4 phage purification by affinity chromatography after its
modification with affinity tags (GST and Histag) by in vivo phage display. As any permanent introduction of
extraneous DNA into a phage genome is strongly unfavourable for medical purposes, integration of foreign motifs
with the phage genome was not applied. The phage was propagated in bacteria expressing fusions of the phage
protein Hoc with affinity tags from bacterial plasmids, independently from the phage expression system.
Results: Elution profiles of phages modified with the specific affinity motifs (compared to non-specific phages)
document their binding to the affinity resins and effective elution with standard competitive agents. Non-specific
binding was also observed, but was 102-105 times weaker than the specific one. GST-modified bacteriophages
were also effectively released from glutathione Sepharose by proteolytic cleavage. The possibility of proteolytic
release was designed at the stage of expression vector construction. Decrease in LPS content in phage
preparations was dependent on the washing intensity; intensive washing resulted in preparations of 11-40 EU/ml.
Conclusions: Affinity tags can be successfully incorporated into the T4 phage capsid by the in vivo phage display
technique and they strongly elevate bacteriophage affinity to a specific resin. Affinity chromatography can be
considered as a new phage purification method, appropriate for further investigations and development.
Background
Phage particle purification is important for two different
issues: general investigation of bacteriophage particles, i.
e. phage biology studies, and for therapeutic applications
of bacteriophages. The first issue successfully applies gra-
dient centrifugation of bacteriophage lysates, in caesium
or saccharose [1-3]. In this case the limiting factor is
mainly the amount of a bacteriophage batch that can be
obtained by a single round of centrifugation. Neverthe-
less, the method can be sufficient for many laboratory-
scale applications. Therapeutic use of bacteriophages
requires large-scale preparations that may be obtained by
various chromatography techniques [4-6]. In these
techniques bacteriophages are generally expected to
behave as “protein-like” fractions with no specificity. This
approach probably provides the best results, although
most bacteriophages are spatially expanded polyhedrons
with very long tails, different from single protein mole-
cules. Bacteriophages also constitute a very diverse and
non-homogeneous group [7]. Therefore any methods are
effective usually only for a selected group of phage
strains. The problem of effective removal of protein and
non-protein (mainly lipopolysaccharide: LPS) bacterial
residuals still limits the therapeutic applications of some
phages. So that the meaning is clear in acute infections,
patients of a poor general condition, low immunological
status, and in cases that apparently require parenteral
injections. Even investigations of phage impact on higher
organisms, i.e. immunological and other physiological
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assays in vivo, often require large amounts of highly puri-
fied phages. In these cases currently used procedures still
do not provide satisfactory results and there is an impor-
tant need to develop phage purification methods.
Affinity chromatography is one of the most efficient
protein purification strategies [8]. This technique com-
prises a one-step procedure with a purification level in
the order of several thousand-fold, adaptable for various
proteins, heterogeneous in their size, shape, charge, and
other properties. Affinity chromatography is based on
interactions of an affinity tag, genetically incorporated
into the protein of interest, and a carbohydrate resin,
which is enriched with a specific, tag-binding motif/
agent. After expression in bacteria (or other), the recom-
bined target protein is able to interact specifically with
the resin. Therefore washing of all other proteins and
contaminations, and elution of the protein are possible.
Moreover, this is usually simple and effective. Introdu-
cing affinity chromatography into the methods of bac-
teriophage purification can result in a simple and
effective procedure, but it requires the placement of spe-
cific affinity tags on bacteriophage capsids.
The technique that enables fusion of a foreign peptide,
protein domain or even a relatively large protein with a
structural protein of a viral particle is phage display.
Foreign peptides are presented on the outer surface of a
viral coat, often in many copies per capsid [9]. It is not
complicated to introduce short oligopeptides, and fila-
mentous phages have been extensively used in these
kinds of modifications. Icosahedral phages, e.g. lambda
phage or T7, can serve as efficient platforms for large
protein display [10-12].
T4 is also one of the large, icosahedral phages that
may serve as a display platform. Importantly, it is not
lysogenic (in contrast to the lambda phage), which has
often been postulated as a requisite of therapeutic
phages [13]. It also represents a numerous phage group
(T4-like phages) sharing substantial homologies and
similarities, and its genome and proteome are very well
described [14,15]. Therefore T4 is a potent model for
general investigations. The T4 bacteriophage capsid has
been modified successfully with extra protein motifs sev-
eral times. Fully active anti-lysozyme IgG, two domains
of the HIV1-CD4 receptor, and PorA peptide from Neis-
seria meningitidis were fused to expose capsid proteins
Soc and Hoc and displayed on the T4 capsid surface
[16-18]. These modifications of the phage were achieved
with the “in vivo phage display technique”, i.e. natural
assemblage in bacteria during a lytic growth cycle was
employed for introducing fusion proteins to the phage
capsid. The fusion comprised gpSoc or gpHoc and the
protein/peptide of interest. The host bacteria expressed
the fusion proteins from a designed expression vector or
fusion protein was generated by integration of tag-
coding sequences to the phage genome. The T4 phage
strains used in the experiments with supplementary
expression vectors had a deletion of soc or a non-sense
mutation in the hoc gene, and thus no native gene pro-
ducts (Hoc or Soc) were incorporated into its head dur-
ing phage assembly. Since Hoc and Soc are not essential
head proteins, these defects do not affect phage viability
[16-18].
Bacteriophage T4 was also found applicable for multi-
component anthrax toxin and for HIV antigen presenta-
tion in in vitro phage display (prepared capsids of T4
hoc- soc- were completed in vitro with purified recombi-
nant Hoc) [19-21].
Here we propose a new method of T4 phage purifica-
tion by affinity chromatography after its modification
with affinity tags (GST and Histag) by in vivo phage dis-
play. This work was based on previous observations of
T4 phage capsid display capacity by Ren and Black [16]
that were combined with standard experience in recom-
binant protein purification by affinity chromatography.
As any permanent introduction of extraneous DNA into
a phage genome is strongly unfavourable for therapeutic
purposes, integration of foreign motifs with the phage
genome was not applied. The phage was propagated in
bacteria expressing fusions of its proteins with affinity
tags.
Results
Expression of the fusion proteins gpHoc with affinity
tags (GST or His tag) was tested in an expression E. coli
strain before the procedure of phage capsid modification
by phage display. Effective production of the recom-
bined proteins was observed both for the vector coding
GST and the vector coding His tag (Figure 1 and 2).
HAP1 phage was applied as the platform for the dis-
play; this phage is defective in the gene hoc, i.e. gpHoc
is not incorporated into the phage capsid [22]. HAP1
takes the place of other Hoc-deprived T4 strains
described in previous studies on Hoc-based phage dis-
play by Ren and Black [16], and by Shivachandra et al.
[20,21]. It is not a specific strain for this work and can
be replaced with another strain derived from T4 but
lacking gpHoc. The expression vectors were used for
simultaneous expression of fusion proteins and propaga-
tion of bacteriophage HAP1 in E. coli, i.e. phage display
in vivo. In this procedure the phage was expected to
incorporate into its capsid gpHoc combined with affinity
tags. Lysis of bacterial expressive cells was observed and
the phage titre was determined in the clarified and fil-
tered lysates.
The affinity of modified bacteriophages to standard
chromatography resins was qualified by comparing their
elution profile from the specific resin with the negative
controls (non-modified phages or phages modified with
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a non-specific tag of the same titre). Figures 3, 4, 5, and
6present the results in the logarithmic scale. Bacter-
iophage HAP1 modified with GST tag and secluded on
the glutathione agarose allowed elution fractions with
phage concentration more than two orders of magnitude
higher than the non-modified phage (Figure 3) and even
three orders of magnitude than the phage modified with
a non-specific tag (Figure 4). Bacteriophage HAP1 modi-
fied with His tag and secluded on the Ni-NTA agarose
(nickel resin) allowed elution fractions with phage con-
centration even almost five orders of magnitude higher
than the non-modified phage (Figure 5) and almost two
orders of magnitude higher than the phage modified
with a non-specific tag (Figure 6). First-step elution frac-
tions were tested for LPS activity; results are presented
in Table 1. Approximately one order of magnitude dif-
ference between results obtained in basic conditions of
washing (100 to 400 EU/ml) and prolonged washing (10
to 40 EU/ml) indicates the strict relation between wash-
ing conditions or intensity and the level of purity of
obtained preparations (Table 1).
The purification procedure of His tag- and GST-modi-
fied phages on Ni-NTA agarose revealed substantially
higher phage concentration in elution fractions com-
pared to final washing samples also in GST-modified
(non-specific) phage. This strongly suggests a relatively
high rate of non-specific phage binding (Figure 6).
Therefore the first fraction of GST-modified phages
after binding and washing in Ni-NTA resin was also
verified for LPS activity. The purification level was com-
paratively good: 40 EU/ml.
Bacteriophage modified with GST was also bound to
the glutathione Sepharose and released by proteolytic
cleavage instead of elution. None of the phage capsid
external proteins contains the short amino acid
sequence recognized by the rare protease AcTEV:
Figure 1 Schema of the expression product used for supplementation of gpHoc defect in the HAP1 phage: fusion of gpHoc, 3-serine
highly soluble motive (for effective proteolysis), sequence recognised by AcTEV protease, and the affinity tag (GST or 6-histidine
motive).
Figure 2 Expression of gpHoc-GST and gpHoc-His tag. Marker (Fermentas SM0661) Total protein profile in the non-induced E. coli strain
transformed with the expression pDEST15 + hoc vector Total protein profile in the IPTG-induced E. coli strain transformed with the expression
pDEST15 + hoc vector: overexpression of Hoc-GST (approx. 70 kDa) Total protein profile in the non-induced E. coli strain transformed with the
expression pDEST17+hoc vector Total protein profile in the IPTG-induced E. coli strain transformed with the expression pDEST17 + hoc vector:
overexpression of Hoc-GST (approx. 40 kDa)
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ENLYFQG (theoretical analysis, T4 genome sequence is
available at http://www.ncbi.nlm.nih.gov/nuccore/
AF158101.6). Bacteriophage was subsequently released,
reaching the concentration 2 × 107 after three days and
3 × 108 after 7 days of proteolysis. This preparation was
also tested for LPS activity and a favourable effect of
prolonged washing was also observed (Table 1).
Discussion
The aim of this work was to verify the possibility of
applying affinity chromatography in bacteriophage puri-
fication, from the perspective of therapeutic purposes.
Elution profiles of phages modified with specific affinity
motifs (Figures 3,4,5 and 6) show substantially higher
phage concentration in elution fractions compared to
final washing samples. This indicates binding of modi-
fied phages to the affinity resins and effective elution
with standard competitive agents. Thus, affinity tags can
be successfully incorporated into the T4 phage capsid
by the in vivo phage display technique and they strongly
elevate bacteriophage affinity to a specific resin. Non-
specific binding was also observed: unmodified phages
or those modified with the non-specific tag were eluted
with the titre 104-105 pfu/ml. Nevertheless, the unspeci-
fic binding is 102-105 times weaker than the specific one
and importantly it does not interfere with the aim of
preparation of purified anti-bacterial active bacterio-
phages for therapeutic use. In this preparation phage
titres that were applied were similar to those obtained
in elution fractions. The amount of the resin was gener-
ally small (as for laboratory use), but the total harvest of
phages can be higher if a larger amount of resin is used
(data not shown), which reflects well-known relevance
in recombined protein purification procedures.
As any permanent introduction of extraneous DNA
into a phage genome is strongly unfavourable for thera-
peutic purposes, integration of foreign motifs with the
phage genome was not applied. The phage was propa-
gated in bacteria expressing fusions of the proteins with
affinity tags from bacterial plasmids, independently from
the phage expression system. Nevertheless, in this work
a non-essential phage gene had to be destroyed to make
an easily accessible position for recombined proteins.
The conditions of binding recombined Hoc with T4 Hoc-
capsids were previously studied by Ren and Black [16],
and by Shivachandra et al. [20,21]. The overall ratio of
Figure 3 Elution profile for the bacteriophage HAP1 modified with GST tag and purified on glutathione Sepharose compared to a
non-modified phage. wash 1 - phage concentration in the washing flow-through (1st litre of washing buffer) wash 2 - phage concentration in
the washing flow-through (2nd litre of washing buffer) wash 3 - phage concentration in the final washing fraction (3rd litre of washing buffer)
elution 1 - phage concentration in the first elution fraction elution 2 - phage concentration in the second elution fraction elution 3 - phage
concentration in the third elution fraction elution 4 - phage concentration in the fourth elution fraction (modified phage only) elution 5 - phage
concentration in the fifth elution fraction (modified phage only)
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binding was shown to vary among 20-40 copies while
there are 155 possible positions on the T4 capsid. The
second group compared the frequency of phage display
for N-terminal and C-terminal Hoc fusions, comparing
them to mutagenesis data mapping the capsid binding
site to the C-terminal domain of Hoc. They found that
N-terminal fusion was about 500-fold more frequently
incorporated than C-terminal and the saturation ratio
was about 30:1 (250-500 nM). As the affinity of N-term-
inal recombined Hoc for the gp23 hexamers remains
very high, it may reach the maximum number in some
conditions [16,20,21]. For further simplification of the
system, our group considered application of non-modi-
fied phages too. Competition between wild type proteins
(expressed from the phage genome) and the recombined
ones (from vectors) decreases the frequency of affinity
tags’ incorporation but it still offers an advantage in
comparison to non-specific binding of non-modified
phages (Dabrowska et al., unpublished data). Impor-
tantly, in this case there are many more target proteins
(almost all capsid external ones) that should be investi-
gated, as well as a possibility of developing the method
for other T4-like phages. These issues should be pro-
posed for further investigations and we intend to
present them next, as further verification of this meth-
od’s universality.
Bacteriophages were also effectively released from the
glutathione Sepharose by proteolytic cleavage. The pos-
sibility of proteolytic release was designed at the stage of
expression vector construction: the sequence coding for
the protease-recognized motif (GAAAACCTGTATTTT-
CAGGGC: ENLYFQG, AcTEV protease) was introduced
by a PCR primer between the hoc gene and the affinity
motif. The proteolytic reaction “in the resin” cuts the
recombinant proteins incorporated into the phage cap-
sid, leaving the affinity motif bound to the resin and
releasing the phage without the foreign motif on its cap-
sid. This possibility is of great importance, as it allows
final purified phages without artificial elements, imitat-
ing natural, non-modified ones. Potential sensitivity of a
phage capsid to a rare protease cannot be excluded;
therefore it should be determined previously. A theoreti-
cal analysis of T4 phage external proteins showed no
sequences susceptible to cleavage (T4 genome sequence
is available at http://www.ncbi.nlm.nih.gov/nuccore/
AF158101.6). Additionally, in the test of phage activity
(double-layer titration) after incubation with the pro-
tease no decrease of phage activity was observed (data
Figure 4 Elution profile for the bacteriophage HAP1 modified with GST tag and purified on glutathione Sepharose compared to the
same phage (HAP1) modified with a non-specific tag. wash - phage concentration in the final washing flow-through (4th litre of washing
buffer) elution 1 - phage concentration in the first elution fraction elution 2 - phage concentration in the second elution fraction elution 3 -
phage concentration in the third elution fraction elution 4 - phage concentration in the fourth elution fraction
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not shown). Even such complicated bacteriophage cap-
sids as T4 can be deprived of artificial binding motifs by
specific proteolytic cleavage, released, and remain active.
Endotoxin assays show that a simple washing proce-
dure allows most endotoxins to be removed: usual LPS
contents in raw lysates exceed 104 EU/ml, and in pre-
paration of phage purified with affinity chromatography
or released by the protease or by competitive elution it
is 100-1000 times lower. The intensity of washing corre-
sponds to the decrease of endotoxin level. These results
suggest that further procedure optimisation (e.g. binding
and/or washing conditions) could further improve the
quality of the purified product.
The phage purification problem is growing with the
new interest in phage therapy that results from the crisis
of antibiotic resistance in bacteria. Phages, unable to
infect eukaryotic cells but strongly active against bac-
teria, are an alternative to antibiotic therapy of bacterial
infections. They are also a prospect in cases of allergy.
Available data indicate high effectiveness and safety of
bacteriophage therapy. Complete independence from
antibiotics’ antimicrobial mechanisms was shown, i.e.
bacteriophages do not follow antibiotics’ cross-resistance
and can be fully effective against antibiotic-resistant bac-
teria [23-27]. Nevertheless, one of the main limitations
for phage therapy is the purification of active phages
from lysates and separation from bacterial residues.
Large-scale methods require simplification of procedures
and the therapeutic purpose emphasizes the problem of
safety. We propose affinity chromatography as an easy,
efficient one-step purification strategy. The resins were
adapted from standard protein affinity chromatography
and are known to be effective, simple, and safe. In vivo
phage display enables even a very large amount of
phages and it reduces the preparation procedure to a
simple one-step microbiological culture. Based on these
initial results, affinity chromatography can be considered
as a new phage purification method, appropriate for
further investigations and development.
Conclusions
Affinity tags can be successfully incorporated into the
T4 phage capsid by the in vivo phage display technique
and they strongly elevate bacteriophage affinity to a
Figure 5 Elution profile for the bacteriophage HAP1 modified with His tag and purified on Ni-NTA agarose compared to a non-
modified phage. wash 1 - phage concentration in the washing flow-through (1st litre of washing buffer) wash 2 - phage concentration in the
washing flow-through (2nd litre of washing buffer) wash 3 - phage concentration in the final washing fraction (3rd litre of washing buffer) elution
1 - phage concentration in the first elution fraction (imidazole 100 mM) elution 2 - phage concentration in the second elution fraction
(imidazole 200 mM) elution 3 - phage concentration in the third elution fraction (imidazole 300 mM) elution 4 - phage concentration in the
fourth elution fraction (imidazole 400 mM) elution 5 - phage concentration in the fifth elution fraction (imidazole 500 mM)
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specific resin. Affinity chromatography can be consid-
ered as a new phage purification method, appropriate
for further investigations and development.
Methods
Bacteriophages and bacteria
T4 phage from the American Type Culture Collection
(ATCC, USA), HAP1 phage from the IIET Microor-
ganisms Collection: HAP1 is a T4 phage mutant with a
nonsense mutation in the hoc gene with no functional
gpHoc. In the HAP1 hoc gene the transition C496®T
occurs, thereby generating a nonsense mutation
Gln166® orche stop codon which was confirmed to
stop incorporation of Hoc into the phage capsid [22].
Escherichia coli expression strains B834 and Rosetta2
(Novagen), transformed with expression plasmids car-
rying the hoc gene in N-terminal fusion with affinity
tags.
Figure 6 Elution profile for the bacteriophage HAP1 modified with GST tag and purified on Ni-NTA agarose compared to the same
phage (HAP1) modified with a non-specific tag. wash 1 - phage concentration in the washing flow-through (1st litre of washing buffer)wash
2 - phage concentration in the washing flow-through (2nd litre of washing buffer)wash 3 - phage concentration in the washing flow-through
(3rd litre of washing buffer)wash 4 - phage concentration in the final washing fraction (4th litre of washing buffer)elution 1 - phage concentration
in the first elution fraction (imidazole 100 mM)elution 2 - phage concentration in the second elution fraction (imidazole 200 mM)elution 3 -
phage concentration in the third elution fraction (imidazole 300 mM)elution 4 - phage concentration in the fourth elution fraction (imidazole
400 mM)elution 5 - phage concentration in the fifth elution fraction (imidazole 500 mM)
Table 1 Endotoxin content in bacteriophage preparations obtained in affinity chromatography of bacteriophages
displaying affinity tags
Bacteriophage preparation LPS activity (SD) [EU/
ml]
Bacteriophage modified with GST tag and purified on glutathione Sepharose (Figure 3) 186 (124)
Bacteriophage modified with GST tag and purified on glutathione Sepharose, prolonged washing (Figure 4) 13 (2)
Bacteriophage modified with His tag and purified on Ni-NTA agarose (Figure 5) 253 (172)
Bacteriophage modified with His tag and purified on Ni-NTA agarose, prolonged washing (Figure 6) 16 (1)
Bacteriophage modified with GST tag and purified on Ni-NTA agarose (non-specific), prolonged washing 40 (2)
Bacteriophage modified with GST tag and purified on glutathione Sepharose, released by proteolysis 363 (47)
Bacteriophage modified with GST tag and purified on glutathione Sepharose, released by proteolysis, prolonged
washing
11 (1)
The endotoxin assay was the Limulus Amebocyte Lysate Assay (Lonza, USA). It is based on activation of pro-enzyme in the Limulus Amebocyte Lysate by
endotoxin of Gram-negative bacteria. The activated enzyme digests the non-colour substrate Ac-Ile-Glu-Ala-Arg-pNA, resulting in the molecule pNA that is
spectrophotometrically detected at 405-410 nm after stopping the reaction with 25% acetic acid. The correlation between endotoxin concentration and
absorbance is linear within the range 0.1-1 EU/ml; therefore all the samples were diluted to this range. All the probes were doubled for the detection. The
concentration in a sample was estimated in comparison to the solutions of an endotoxin standard (supplied with the LAL kit), also doubled. Reaction conditions:
10 min. 37°C for the lysate, 8 min. 37°C for LAL substrate, then stopping the reaction and detection in 96-well plates. Only apyrogenic equipment was used (once
and never reused) in the test.
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Expression vectors
Vectors were prepared using GATEWAY recombination
technology following the manufacturer’s instructions
(Invitrogen). Cloning was carried out with polymerase
chain reaction (PCR) products. Double PCR was applied
for introduction of long flanking regions consisting of
recombination regions and a coding region for rare pro-
tease AcTev (Invitrogen). Primers: PCR1 forward
GAAAACCTGTATTTTCAGGGCAGCAGCAGCAT
GACTTTTACAGTTG, PCR1 reverse: GGGGACCA
CTTTGTACAAGAAAGCTGGGTCCTATGGATAGG
TATAGATGATACC, PCR2 forward: GGGGACAAG
TTTGTACAAAAAAGCAGGCTCCGAAAACCTGTA
TTTTCAGGGC, and PCR2 reverse: GGGGACCA
CTTTGTACAAGAAAGCTGGGTCCTATGGATAGGT
ATAGATGATACC. Entry clones were prepared with
the donor vector pDONR201. Destination clones were
prepared with pDEST15 (GST tag) or pDEST17 (His
tag) (Figure 1). Control DNA sequencing was performed
at the Institute of Biochemistry and Biophysics, Polish
Academy of Sciences, DNA Sequencing and Oligonu-
cleotide Synthesis Laboratory, Warsaw, Poland. Isolated
plasmid DNA (PlasmidMini A&A Biotechnology) was
applied in the reaction of sequencing (3730 DNA Analy-
zer, Applied Biosystems, Hitachi, DNA Sequencing Kit-
Big Dye™ Terminator Cycle Sequencing version 1.1):
94°C for 10 s, 52°C for 20 s, 60°C for 4 min, 25 cycles;
100 ng DNA, 1 μl of 5 μM primer, 3 μl buffer, 1 μl
enzyme premix, H2O adjusted to 10 μl (http://oligo.ibb.
waw.pl).
The expression of the recombined proteins was con-
trolled in the bacterial lysate (lysis by freeze-thawing) by
SDS-PAGE of total bacterial protein profile and by test
affinity chromatography with binding, washing (50 mM
Na2HPO4, 300 mM NaCl, pH 7.5) and elution (glu-
tathione buffer for GST-tag: 40 mM glutathione, 50 mM
Tris, pH 8.0, or imidazole buffer for His-tag: 100-500
mM imidazole, 50 mM Na2HPO4, 300 mM NaCl, pH
7.5) followed with SDS-PAGE. Strains were used for
further procedures only if effective expression of the
modified proteins was noticed.
In vivo phage display
Bacterial cells were grown at 37°C until OD600 0.7 was
reached. Next they were transferred to fresh media con-
taining 0.05-0.1 mM IPTG and approx. 106-107 pfu/ml
HAP1 (1:100 - 1:1000 of total culture volume), so that
the induction of protein expression and phage infection
took place at the same time. Infected cells were grown
at 37°C for 8 hours. When bacterial cell lysis was
observed, lysates were filtered and used for affinity chro-
matography. Control preparations: (i) not modified
phage HAP1 or T4, (ii) phage HAP1 modified with a
non-specific affinity tag. Control preparations had
identical phage concentration compared to specific tag
modified ones: 5 × 108 pfu/ml. They were purified and
eluted identically.
Purification procedure
Filtered lysates were incubated with 2 ml of glu-
tathione Sepharose (GE Healthcare) or Ni-NTA agar-
ose (QiaGen) overnight at 4°C. Next the unbound
fraction was removed, and the resin was washed with 3
litres of sodium phosphate buffer (50 mM Na2HPO4,
300 mM NaCl, pH 7.5). Alternatively the washing pro-
cedure was prolonged: 4 litres of sodium phosphate
buffer, and in the case of His-tag modification the
phosphate buffer was enriched with imidazole 50 and
100 mM. Elution of specifically bound phage particles
from Ni-NTA agarose was carried out competitively
with a 100-500 mM gradient of imidazole. In the case
of glutathione Sepharose two strategies of product
release were used: (i) competitive elution with 40 mM
reduced glutathione (5 eluted fractions), each incu-
bated at least 20 min with the elution buffer, or (ii)
proteolytic tag cleavage with AcTEV protease (Invitro-
gen) for 7 days.
Phage preparations were titrated by the two-layer
method of Adams [28] and tested by Limulus amebocyte
lysate assay (Lonza). Example experiments are presented
in the logarithmic scale.
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